Results 121 to 130 of about 3,492,883 (216)

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). [PDF]

, 2018
The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents.
Jung, Kyungsuk, Kang, Hyunseok, Mehra, Ranee   +2 more
core   +2 more sources

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors

BMC Cancer, 2012
Background Epidermal growth factor receptor (EGFR) signaling plays an important role in non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been effective in treating a subset of patients bearing somatic EFGR mutations. However,
Ghosh Gargi, Lian Xiaojun, Kron Stephen J, Palecek Sean P   +3 more
doaj   +1 more source

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. [PDF]

, 2015
BackgroundThis retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by evaluating the impact of prior activity and intervening time interval.MethodsEighty ...
Eng, C, Falchook, GS, Fu, S, Garrett, C, George, GC, Hess, K, Hong, DS, Janku, F, Karp, D, Kopetz, S, Kurzrock, R, Liu, X, Meric-Bernstam, F, Naing, A, Overman, MJ, Piha-Paul, SA, Raghav, K, Subbiah, V, Tsimberidou, AM, Wheler, JJ, Zinner, R   +20 more
core   +2 more sources

miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells

Journal of drug targeting (Print), 2017
Non-small cell lung cancer (NSCLC) is the major cause of lung cancer-related deaths. Erlotinib is an effective drug for NSCLC patients, but its effect in advanced NSCLC is compromised because of the drug resistance.
Weihua Zhang, Jun Lin, Peng Wang, Jian Sun   +3 more
semanticscholar   +1 more source

Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance [PDF]

Biochemical Pharmacology, 2010
In recent years, a number of TKIs (tyrosine kinase inhibitors) targeting epidermal growth factor receptor (EGFR) family have been synthesized and some have been approved for clinical treatment of cancer by the FDA. We recently reported a new pharmacological action of the 4-anilinoquinazoline derived EGFR TKIs, such as lapatinib (Tykerb) and erlotinib ...
Ye-Hong, Kuang, Tong, Shen, Xiang, Chen, Kamlesh, Sodani, Elizabeth, Hopper-Borge, Amit K, Tiwari, Jeferson W K K, Lee, Li-Wu, Fu, Zhe-Sheng, Chen   +8 more
openaire   +2 more sources

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, Volume 45, Issue 3, Page 455-475, May/June 2026.
ABSTRACT Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

eLife, 2015
Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In characterizing early transcriptional changes following drug treatment of mutant EGFR-addicted cells, we ...
S Michael Rothenberg, Kyle Concannon, Sarah Cullen, Gaylor Boulay, Alexa B Turke, Anthony C Faber, Elizabeth L Lockerman, Miguel N Rivera, Jeffrey A Engelman, Shyamala Maheswaran, Daniel A Haber   +10 more
doaj   +1 more source

Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. [PDF]

, 2019
Dysregulation of the seven-transmembrane (7TM) receptor Smoothened (SMO) and other components of the Hedgehog (Hh) signaling pathway contributes to the development of cancers including basal cell carcinoma (BCC) and medulloblastoma (MB).
Abagyan, Ruben, Chahal, Kirti Kandhwal, Chen, Clark C, Durden, Donald L, Kufareva, Irina, Li, Jie, Parle, Milind, Wechsler-Reya, Robert J   +7 more
core   +1 more source

Sphingosine‐1‐Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third‐Generation EGFR Inhibitor

MedComm, Volume 7, Issue 5, May 2026.
• S1PR3 drives metastasis in EGFR TKI‐resistant lung cancer by activating RAC1‐PAK1 signaling and promoting EMT. • FGFR1‐STAT4 axis upregulates S1PR3, enabling metastatic escape in resistant tumors. • Targeting S1PR3 or FGFR1 suppresses metastasis, offering a therapeutic strategy for EGFR TKI‐resistant lung cancer.
Mengzhen Lai, Jiaying Chen, Ye Qin, Hui Zhang, Zilu Pan, Tao Zhang, Linjiang Tong, Haotian Tang, Gang Bai, Qiupei Liu, Yan Li, Fang Feng, Peiran Song, Yingqiang Liu, Yi Chen, Yan Fang, Bencan Tang, Meiyu Geng, Ker Yu, Hao Chen, Jian Ding, Hua Xie   +21 more
wiley   +1 more source